Epitope selection & validation serviceT cell immunomonitoring using MHC technologies
Our proprietary technology for UV-induced MHC-peptide exchange is ideally suited for high-throughput screening of peptide-binding to the MHC class I complexes.
Moreover, combinatorial coding enables fast finding of relevant peptide-specific cytotoxic T cells.
UV-induced peptide exchange technology
For high-throughput screening of peptide-binding to the MHC class I complex. You can, for example, screen and select relevant cytotoxic T cell epitopes for vaccines, immuno-therapies or monitoring.
This enables fast finding of specific T cells. For example, monitor and characterise multiple antigen-specific CD8+ T cell populations in a single sample.
T cell Epitope Service testing
Particularly interesting for pharmaceutical companies that need immunogenicity testing for e.g. vaccine development and cancer treatment.
Follow the lead of companies as Neon Therapeutics, Kite Pharma, Immatics Biotechnologies GMBH, who have obtained a license and incorporate these technologies in their development and therapy monitoring tracks. Contact [email protected]
Licensing press releases
History of development
Sanquin has done outstanding research for many years regarding human leukocytes and cellular immunology. We combine this with high-quality diagnostic laboratory services and extensive experience in the production of immunological reagents.In 1999, divisions Reagents / Research in Amsterdam and The Netherlands Cancer Institute (NKI) in Amsterdam launched an MHC-multimer core facility at Sanquin’s premises. This has resulted in a fast expanding product range for T cell research.The MHC technologies, developed together by the NKI and Sanquin, are patent-protected in a wide territory by patent families WO 2006/080837 (including, but not limited to EP 1841791B1 and US 9,079,941B2) and WO2010/060439 (including but not limited to EP2362882B1 and US9151757B2).